Bank Julius Baer & Co. Ltd, Zurich Mirati Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 24, 2023	BUY	$36.13 - $49.49 $51,810 - $70,968	1,434 New	1,434 $52,000
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $2,192 - $3,255	-60 Reduced 4.02%	1,434 $53,000
Q4 2022 Jan 24, 2023	SELL	$41.27 - $98.62 $410,760 - $981,564	-9,953 Reduced 86.95%	1,494 $68,000
Q3 2022 Nov 04, 2022	BUY	$59.5 - $86.7 $533,477 - $777,352	8,966 Added 361.39%	11,447 $799,000
Q2 2022 Jul 22, 2022	BUY	$39.16 - $88.71 $28,586 - $64,758	730 Added 41.69%	2,481 $167,000

Q1 2022 May 09, 2022	BUY	$75.82 - $150.97 $132,760 - $264,348	1,751 New	1,751 $144,000
Q2 2021 Jul 23, 2021	SELL	$144.0 - $179.73 $432,000 - $539,190	-3,000 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$158.92 - $221.61 $310,529 - $433,025	-1,954 Reduced 39.44%	3,000 $514,000
Q4 2020 Feb 24, 2021	BUY	$162.05 - $240.27 $306,760 - $454,831	1,893 Added 61.84%	4,954 $1.09 Million
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $9,885 - $14,656	61 Added 2.03%	3,061 $1.09 Million
Q2 2020 Aug 12, 2020	SELL	$72.01 - $120.39 $144 - $240	-2 Reduced 0.07%	3,000 $343,000
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $209,479 - $348,862	3,002 New	3,002 $231,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.